【UCREST 0005 交流专区】（前名 PALETTE）

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 May 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 May 2020	31 May 2019	31 May 2020	31 May 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	0	2,917	12,276	28,805
2	Profit/(loss) before tax	-11,882	-4,064	-22,498	7,098
3	Profit/(loss) for the period	-9,709	-3,232	-20,325	5,885
4	Profit/(loss) attributable to ordinary equity holders of the parent	-9,709	-3,232	-20,325	5,885
5	Basic earnings/(loss) per share (Subunit)	-2.09	-0.88	-4.38	1.60
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0400		0.0820

icy97

UCREST BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	Proposed private placement of up to 20.00% of the total number of issued shares of UCrest
No. of shares issued under this corporate proposal	25,000,000
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.1223
Par Value($$) (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	496,349,875
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 22,840,191.600
Listing Date	25 Sep 2020

icy97

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

UCREST BERHAD

Particulars of Substantial Securities Holder

Name	MISS NG GEOK LUI
Nationality/Country of incorporation	Singapore
Descriptions (Class)	Ordinary Shares
Name of registered holder	Ng Geok Lui

Date interest acquired & no of securities acquired
Date interest acquired	24 Sep 2020
No of securities	25,000,000
Circumstances by reason of which Securities Holder has interest	Private Placement
Nature of interest	Direct Interest
Total no of securities after change
Direct (units)	25,000,000
Direct (%)	5.037
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Date of notice	08 Oct 2020
Date notice received by Listed Issuer	08 Oct 2020

icy97

UCREST BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	Proposed private placement of up to 20.00% of the total number of issued shares of UCrest
No. of shares issued under this corporate proposal	10,600,000
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.1297
Par Value($$) (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	506,949,875
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 24,215,011.600
Listing Date	27 Oct 2020

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Aug 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Aug 2020	31 Aug 2019	31 Aug 2020	31 Aug 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,275	7,514	3,275	7,514
2	Profit/(loss) before tax	1,192	143	1,192	143
3	Profit/(loss) for the period	1,192	143	1,192	143
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,192	143	1,192	143
5	Basic earnings/(loss) per share (Subunit)	0.25	0.03	0.25	0.03
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0400		0.0400

icy97

UCREST BERHAD

Particulars of substantial Securities Holder

Name	MISS NG GEOK LUI
Nationality/Country of incorporation	Singapore
Descriptions (Class)	Ordinary Shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	26 Oct 2020	10,600,000	Others	Direct Interest
	Name of registered holder	Ng Geok Lui
	Description of "Others" Type of Transaction	Private Placement

Circumstances by reason of which change has occurred	Private Placement
Nature of interest	Direct Interest
Direct (units)	35,600,000
Direct (%)	7.022
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Total no of securities after change	35,600,000
Date of notice	27 Oct 2020
Date notice received by Listed Issuer	27 Oct 2020

Notice of Person Ceasing (Section 139 of CA 2016)

UCREST BERHAD

Particulars of Substantial Securities Holder

Name	MISS NG GEOK LUI
Nationality/Country of incorporation	Singapore
Descriptions (Class)	Ordinary Shares
Name of registered holder	Ng Geok Lui
Date of cessation	08 Dec 2020

No of securities disposed	35,600,000
Circumstances by reason of which a person ceases to be a substantial shareholder	Disposal in Open Market
Nature of interest	Direct Interest
Date of notice	15 Dec 2020
Date notice received by Listed Issuer	15 Dec 2020

UCREST BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	Proposed private placement of up to 20.00% of the total number of issued shares of UCrest
No. of shares issued under this corporate proposal	58,704,575
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.1421
Par Value($$) (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	565,827,450
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 32,571,948.110
Listing Date	17 Dec 2020

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

UCREST BERHAD

Particulars of Substantial Securities Holder

Name	MISS NG GEOK LUI
Nationality/Country of incorporation	Singapore
Descriptions (Class)	Ordinary Shares
Name of registered holder	Ng Geok Lui

Date interest acquired & no of securities acquired
Date interest acquired	16 Dec 2020
No of securities	58,704,575
Circumstances by reason of which Securities Holder has interest	Private Placement
Nature of interest	Direct Interest
Total no of securities after change
Direct (units)	58,704,575
Direct (%)	10.375
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Date of notice	17 Dec 2020
Date notice received by Listed Issuer	17 Dec 2020

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Aug 2021

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Aug 2021	31 Aug 2020	31 Aug 2021	31 Aug 2020
		$$'000	$$'000	$$'000	$$'000

1	Revenue	7,037	3,275	7,037	3,275
2	Profit/(loss) before tax	-212	1,192	-212	1,192
3	Profit/(loss) for the period	-212	1,192	-212	1,192
4	Profit/(loss) attributable to ordinary equity holders of the parent	-212	1,192	-212	1,192
5	Basic earnings/(loss) per share (Subunit)	-0.03	0.25	-0.03	0.25
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1000		0.1000

icy97

UCREST BERHAD

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-25112021-00002
Subject	(I) MEMORANDUM OF UNDERSTANDING WITH RUSSIAN DIRECT INVESTMENT FUND ("RDIF") (II) MASTER SERVICE AGREEMENT BETWEEN UCREST BERHAD'S ("UCREST") WHOLLY OWNED SUBSIDIARY, UCREST TECHNOLOGY LIMITED, AND LIMITED LIABILITY COMPANY HUMAN VACCINE, A WHOLLY OWNED SUBSIDIARY OF RDIF
Description	REPLY TO QUERY FROM BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES") DATED 25 NOVEMBER 2021 PERTAINING TO (I) MEMORANDUM OF UNDERSTANDING WITH RUSSIAN DIRECT INVESTMENT FUND ("RDIF") ("MOU") (II) MASTER SERVICE AGREEMENT BETWEEN UCREST BERHAD'S ("UCREST") WHOLLY OWNED SUBSIDIARY, UCREST TECHNOLOGY LIMITED, AND LIMITED LIABILITY COMPANY HUMAN VACCINE, A WHOLLY OWNED SUBSIDIARY OF RDIF ("MSA")
Query Letter Contents	We refer to your Company’s announcement dated 24 November 2021, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- 1) The date on which the Technology Transfer Agreement was entered into. 2) The names of the parties to the Technology Transfer Agreement. 3) The date of approval of the import license and the name of the approving authority. 4) The date on which the Quality Agreement was signed. 5) To clarify whether the Quality Agreement was signed by all 3 contract manufacturers that were announced by UCrest on 19 May 2021 and 9 June 2021. 6) The expected date of commencement of manufacturing of the vaccines.
Please refer to the attachment below for the reply to the query letter from Bursa Malaysia Securities Berhad. This announcement is dated 26 November 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3213336

Attachments UCrest-Bursa Query.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	UCREST BERHAD ("UCREST" OR "THE COMPANY")- AGREEMENT WITH DOCSUN BIOMED LIMITED
The Board of Directors of UCrest wishes to announce that the Company had on 7 October 2022 signed agreement to invest and to lead the investment of Docsun Biomed Limited (“Docsun”), a holding company that owns a leading US medical technology company that has developed non-contact, non-invasive, non-intrusive vital signs and it has a subsidiary in Taiwan and India. The Company had also on 7 October 2022, signed an Exclusive Distribution Agreement (“EDA”) with Docsun where Docsun is appointed by UCrest as the exclusive distributor for the US market of the iMedic-Docsun integrated products. Please refer to the attachment for further information.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3298582

Attachments UCrest-Agreement with DOCSUN.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	UCREST BERHAD ("UCREST" OR "THE COMPANY")- BUSINESS PARTNERSHIP AGREEMENT WITH MEDIPRIMA HEALTHCARE (M) SDN. BHD.
The Board of Directors of UCrest wishes to announce that the Company had on 14 March 2024 entered into a Business Partnership Agreement ("BPA") with Mediprima Healthcare (M) Sdn. Bhd. (“Mediprima”) to digitalize the clinics with digital health, integrate Artificial Intelligence (“AI”) and Internet of Medical Things (“IoMT”) into the medical services, leading the primary care services to a new era, elevating the healthcare industry to the next level. Please refer to the attachment for the details of the announcement. This announcement is dated 14 March 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3430551

Attachments Business Partnership Agreement with Mediprima Healthcare (M) Sdn Bhd.pdf

icy97

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-15032024-00002
Subject	UCREST BERHAD (UCREST OR THE COMPANY) - BUSINESS PARTNERSHIP AGREEMENT WITH MEDIPRIMA HEALTHCARE (M) SDN. BHD. (BPA)
Description	UCREST BERHAD ("UCREST" OR "THE COMPANY") - REPLY TO QUERY FROM BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES") DATED 15 MARCH 2024 PERTAINING TO THE BUSINESS PARTNERSHIP AGREEMENT ("BPA") WITH MEDIPRIMA HEALTHCARE (M) SDN. BHD.
Query Letter Contents	We refer to your Company’s announcement dated 14 March 2024, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- 1) The duration of BPA, including its commencement and expiry date. 2) Whether the BPA is renewable, and if so, details of such renewal. 3) The value of the BPA, or the basis for determining the payment to be made to Ucrest.
We refer to the announcement made by the Company dated 14 March 2024 pertaining to the BPA with Mediprima Healthcare (M) Sdn. Bhd. (“Announcement”) and the query from Bursa Securities dated 15 March 2024 (IQL-15032024-00002) in relation to the Announcement (“Bursa Query”). Unless otherwise stated, the terms used throughout this announcement shall have the same meanings as defined in the Announcement. Please refer to the attachment for the reply to the query letter from Bursa Securities.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3431366

Attachments Reply to Bursa Query in relation to the BPA - UCrest.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	UCREST BERHAD ("UCREST" OR "THE COMPANY")- BUSINESS PARTNERSHIP AGREEMENT WITH STAYONLINE LTD
The Board of Directors of UCrest wishes to announce that the Company had on 21 March 2024 entered into a Business Partnership Agreement ("BPA") with StayOnline Ltd (“StayOnline”) to digitalize the healthcare industry with Artificial Intelligence (“AI”) and Internet of Medical Things (“IoMT”) into StayOnline digital payment platform offering intelligent medical services to the population in Rwanda, Kenya, Uganda and Zambia, elevating the healthcare industry to a new era. Please refer to the attachment for the details of the announcement. This announcement is dated 21 March 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3432354

Attachments Business Partnership Agreement with StayOnline Ltd.pdf

icy97

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-25032024-00001
Subject	UCREST BERHAD ("UCREST" OR THE "COMPANY") - BUSINESS PARTNERSHIP AGREEMENT WITH STAYONLINE LTD ("BPA")
Description	UCREST BERHAD ("UCREST" OR "THE COMPANY") - REPLY TO QUERY FROM BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES") DATED 25 MARCH 2024 PERTAINING TO THE BUSINESS PARTNERSHIP AGREEMENT ("BPA") WITH STAYONLINE LTD
Query Letter Contents	We refer to your Company’s announcement dated 21 March 2024, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- 1) Whether the BPA is renewable, and if so, details of such renewal. 2) The value of the BPA, or the basis for determining the payment to be made to Ucrest.
We refer to the announcement made by the Company dated 21 March 2024 pertaining to the BPA with StayOnline Ltd (“Announcement”) and the query from Bursa Securities dated 25 March 2024 (IQL-25032024-00001) in relation to the Announcement (“Bursa Query”). Unless otherwise stated, the terms used throughout this announcement shall have the same meanings as defined in the Announcement. Please refer to the attachment for the reply to the query letter from Bursa Securities.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3433735

Attachments Reply to Bursa Query in relation to the BPA with StayOnline Ltd - UCrest.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	UCREST BERHAD ("UCREST" OR "THE COMPANY")- BUSINESS PARTNERSHIP AGREEMENT WITH MDC ASIA LINK BERHAD
The Board of Directors of UCrest wishes to announce that the Company had on 3 April 2024 entered into a Business Partnership Agreement ("BPA") with MDC Asia Link Berhad (“MDC”) to digitalize with Artificial Intelligence (“AI”) and Internet of Medical Things (“IoMT”) with iMedic™ platform. The objective of the partnership is to take the standard of care in the dental industry to the next level, provide the patients with the highest level of care where MDC will adopt the iMedic™ platform as the Clinic Management System (“CMS”). Please refer to the attachment for the details of the announcement. This announcement is dated 3 April 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3435894

Attachments UCrest-Business Partnership Agreement with MDC Asia Link Berhad.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 May 2024

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 May 2024	31 May 2023	31 May 2024	31 May 2023
		$$'000	$$'000	$$'000	$$'000

1	Revenue	4,574	6,207	16,489	13,557
2	Profit/(loss) before tax	814	2,003	4,926	101
3	Profit/(loss) for the period	814	2,003	4,926	101
4	Profit/(loss) attributable to ordinary equity holders of the parent	814	2,003	4,926	101
5	Basic earnings/(loss) per share (Subunit)	0.11	0.29	0.66	0.02
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0600		0.0500

icy97

Type	Announcement
Subject	OTHERS
Description	UCREST BERHAD ("UCREST" OR "THE COMPANY")- COLLABORATION WITH UNIVERSITI KUALA LUMPUR
The Board of Directors of the Company wishes to announce that the Company has collaborated with Universiti Kuala Lumpur (“UniKL") to promote digital healthcare throughout the campus by launching the iMedic™ Digital Clinic in UniKL campus in Malaysia on 24 September 2024. This is the first iMedic™ Digital Clinic in university campus in the Asia. UCrest has signed a Letter of Intent with UniKL for the industrial-academic collaboration. UCrest and UniKL will jointly develop the Centre of Excellence for digital health that includes the development workshop for digital health that encompasses Artificial Intelligence (AI) in healthcare applications, and Internet of Things (IoT) and the setup of iMedic™ Digital Clinic on campus to put the technologies into real use. The workshop is not only for students as part of the curriculum, but also for practicing doctors in the industry. Students or doctors will be issued a certificate with Continuing Medical Education (CME) by UniKL and UCrest. The plan of the collaboration is to have at least one iMedic™ Digital Clinic on each campus, with the total of 12 campuses within the next few months. The iMedic™ Digital Clinic at UniKL is equipped with multiple sets of wireless digital medical devices such as wireless blood pressure monitors, oximeters, blood glucose meters, digital BMI machines and ECG device.  Vital signs collected from these devices is uploaded automatically to the iMedic™ Cloud hospital. The AI engine will analyse the submitted data and flag out abnormalities and critical readings and automatic escalation to the respective doctors or specialists. Medication will be prescribed and sent to the patients. The Company was of the view that education is an essential piece of the puzzle in the digital transformation of the healthcare system other than continuous development of the technologies. With the joint effort in developing the Center of Excellence with UniKL, the Company would be able to accelerate the digital transformation of the clinics and also assist in shaping the new business model that is scalable, hence increase the efficacy of the patients and efficiency of the patients by multiple folds. Digital health powered by AI and IoT is the next big transformation of the healthcare industry globally and the Company was pleased to have the support of UniKL to take the leading roles in the development of the digital economy in the healthcare industry. UCrest does not foresee any significant risks associated with the collaboration. None of the Directors and/or major shareholders of the Company and/or persons connected to them have any interest, whether direct and/or indirect, in the collaboration. The collaboration will not have any effect on the share capital and substantial shareholders’ shareholdings of the Company. The collaboration is not expected to have a material effect on the earnings per share, net assets per share and gearing of the Company for the financial year ending 31 May 2025. The announcement is dated 24 September 2024.